DAWN Stock Down -11% after 8-Day Loss Streak
Day One Biopharmaceuticals (DAWN) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -9.6% return. The company has lost about $64 Mil in valuation over the last 8 days, with its current market capitalization being $668 Mil. The stock remains 49.4% below its value at the end of 2024. This compares with year-to-date returns of 1.7% for the S&P 500 and -0.5% for the Trefis High Quality Portfolio.
Comparing DAWN Stock Returns With The S&P 500
The following table summarizes the return for DAWN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | DAWN | S&P 500 |
| 1D | -1.4% | -0.0% |
| 8D (Current Streak) | -10.8% | -0.3% |
| 1M (21D) | -1.1% | 0.3% |
| 3M (63D) | -22.6% | 5.4% |
| YTD 2025 | -49.4% | 1.7% |
| 2024 | -13.2% | 23.3% |
| 2023 | -32.2% | 24.2% |
| 2022 | 27.7% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 23 S&P constituents with 3 days or more of consecutive gains and 60 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
| 3D | 17 | 11 |
| 4D | 1 | 39 |
| 5D | 2 | 2 |
| 6D | 2 | 7 |
| 7D or more | 1 | 1 |
| Total >=3 D | 23 | 60 |
Key Financials for Day One Biopharmaceuticals (DAWN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
| Revenues | – | $131.2 Mil |
| Operating Income | $-206.1 Mil | $-217.3 Mil |
| Net Income | $-188.9 Mil | $-95.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
| Revenues | $29.2 Mil | $30.8 Mil |
| Operating Income | $-65.3 Mil | $-41.1 Mil |
| Net Income | $-65.7 Mil | $-36.0 Mil |
The losing streak DAWN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.